Why investors should question Savara's excuse
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Savara hopes to take a leaf out of Insmed’s book
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
